A Phase 2/3 interventional study of E3810 and E3810 in Gastric or Duodenal Ulcers Caused by Low-dose Aspirin, sponsored by Eisai Co., Ltd.. Completed at 49 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-11-26.
Sponsored by Eisai Co., Ltd. · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Stomach Ulcer with a site in Japan — none open to participants now, none under way, none of them phase 3. Stomach Ulcer · Japan.
Among the 29 studies in Stomach Ulcer with a site in Japan, this one is the 5th largest by enrollment of the 20 interventional ones that give a count, is one of 8 that started in 2011, is one of 3 in phase 2/3, and was the 12th registered.
116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
Browse Stomach Ulcer studies →None of the 29 studies in Stomach Ulcer with a site in Japan is open now. The open studies under Stomach Ulcer, anywhere →
Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 18 · Phase 4 2
First in 2000; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 472 is above the median of 298 across 88 interventional studies indexed under Stomach Ulcer.
Median enrollment 400 across the 20 interventional studies, 1,999 across the 6 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 29 have an industry lead sponsor. The 5 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Eisai Co., Ltd. has 6 studies filed under Stomach Ulcer — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Stomach Ulcer with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study to evaluate the effect of preventing recurrence of gastric or duodenal ulcers by administering E3810 5 mg or 10 mg tablets once daily or Teprenone 150 mg/day (50 mg three times daily) as a control to patients receiving low-dose aspirin and thereby examine the superiority of E3810 over Teprenone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
-Confirmed to have acute gastro duodenal mucosal lesions, gastric or duodenal ulcer, or upper gastrointestinal (esophagus, stomach, duodenum) bleeding Confirmed to have reflux esophagitis or long segment Barrett's esophagus
Drug: E3810
Drug: E3810
Drug: Teprenone
Drug pages: Rabeprazole · E-3810
E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
Drug pages: Rabeprazole · E-3810
E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
Cumulative Recurrent Rates of Gastric or Duodenal Ulcers
Mucosal injuries with a white coat measuring 3 mm in diameter will be diagnosed as ulcers. When ulcer is confirmed by endoscopic examination during the trial, it will be regarded as recurrence of ulcer and the trial will be discontinued for the patient involved.
Time frame: 24 weeks
Cumulative Incidence of Bleeding Ulcers
Time frame: 24 weeks
| Milestone | Rabeprazole 5 mg | Rabeprazole 10 mg | Teprenone 150 mg |
|---|---|---|---|
| Started | 156 | 157 | 158 |
| Completed | 138 | 142 | 140 |
| Not completed | 18 | 15 | 18 |
| Withdrew: Adverse event | 4 | 4 | 6 |
| Withdrew: Withdrawal by subject | 4 | 4 | 3 |
| Withdrew: Lack of efficacy | 2 | 0 | 5 |
| Withdrew: Other | 8 | 7 | 4 |
| Events/100 participants/24 weeks | Rabeprazole 5 mg | Rabeprazole 10 mg | Teprenone 150 mg |
|---|---|---|---|
| Cumulative Incidence of Bleeding Ulcers | 0 (0 to 0) | 0 (0 to 0) | 4.6 (2.24 to 9.48) |
Mucosal injuries with a white coat measuring 3 mm in diameter will be diagnosed as ulcers. When ulcer is confirmed by endoscopic examination during the trial, it will be regarded as recurrence of ulcer and the trial will be discontinued for the patient involved.
| Events/100 participants/24 weeks | Rabeprazole 5 mg | Rabeprazole 10 mg | Teprenone 150 mg |
|---|---|---|---|
| Cumulative Recurrent Rates of Gastric or Duodenal Ulcers | 2.8 (1.04 to 7.17) | 1.4 (0.35 to 5.51) | 21.7 (15.84 to 29.27) |
Collected over 24 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rabeprazole 5 mg | — | 10/156 (6.4%) | 48/156 (30.8%) |
| Rabeprazole 10 mg | — | 6/157 (3.8%) | 46/157 (29.3%) |
| Teprenone 150 mg | — | 10/158 (6.3%) | 41/158 (25.9%) |
| Event | Rabeprazole 5 mg | Rabeprazole 10 mg | Teprenone 150 mg |
|---|---|---|---|
| Angina pectorisCardiac disorders | 1/156 | 0/157 | 2/158 |
| Pancreatitis acuteGastrointestinal disorders | 1/156 | 0/157 | 0/158 |
| VomitingGastrointestinal disorders | 1/156 | 0/157 | 0/158 |
| Spinal compression fractureInjury, poisoning and procedural complications | 1/156 | 0/157 | 0/158 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 1/156 | 0/157 | 0/158 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/156 | 0/157 | 0/158 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 1/156 | 0/157 | 0/158 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/156 | 0/157 | 0/158 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/156 | 0/157 | 0/158 |
| Gastric adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/156 | 0/157 | 0/158 |
| Event | Rabeprazole 5 mg | Rabeprazole 10 mg | Teprenone 150 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 25/156 | 22/157 | 25/158 |
| PharyngitisInfections and infestations | 6/156 | 1/157 | 2/158 |
| DiarrhoeaGastrointestinal disorders | 4/156 | 6/157 | 2/158 |
| EczemaSkin and subcutaneous tissue disorders | 1/156 | 6/157 | 1/158 |
| ConstipationGastrointestinal disorders | 1/156 | 5/157 | 6/158 |
| Upper respiratory tract infectionInfections and infestations | 5/156 | 3/157 | 2/158 |
| HypertensionVascular disorders | 0/156 | 5/157 | 3/158 |
| ContusionInjury, poisoning and procedural complications | 4/156 | 0/157 | 3/158 |
| Diabetes mellitusMetabolism and nutrition disorders | 4/156 | 2/157 | 1/158 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/156 | 1/157 | 4/158 |
| Age, Continuous(Years) | Rabeprazole 5 mg | Rabeprazole 10 mg | Teprenone 150 mg | Total |
|---|---|---|---|---|
| Mean | 69.3 ± 8.9 | 70.1 ± 9.6 | 69.4 ± 7.9 | 69.6 ± 8.8 |
| Sex: Female, Male(Participants) | Rabeprazole 5 mg | Rabeprazole 10 mg | Teprenone 150 mg | Total |
|---|---|---|---|---|
| Female | 35 | 36 | 41 | 112 |
| Male | 121 | 121 | 117 | 359 |
| Antiplatelet Drug or Anticoagulant Drug(Participants) | Rabeprazole 5 mg | Rabeprazole 10 mg | Teprenone 150 mg | Total |
|---|---|---|---|---|
| Yes | 30 | 34 | 35 | 99 |
| No | 126 | 123 | 123 | 372 |
| Daily Dose of Low-Dose Aspirin(Participants) | Rabeprazole 5 mg | Rabeprazole 10 mg | Teprenone 150 mg | Total |
|---|---|---|---|---|
| 81 mg | 12 | 14 | 16 | 42 |
| 100 mg | 144 | 143 | 142 | 429 |
| Diagnostic Test of H.pylori. (IgG Antibody)(Participants) | Rabeprazole 5 mg | Rabeprazole 10 mg | Teprenone 150 mg | Total |
|---|---|---|---|---|
| Positive | 72 | 67 | 77 | 216 |
| Negative | 84 | 90 | 81 | 255 |
| Primary Disease(Participants) | Rabeprazole 5 mg | Rabeprazole 10 mg | Teprenone 150 mg | Total |
|---|---|---|---|---|
| Angina Pectoris (Yes) | 68 | 63 | 66 | 197 |
| Angina Pectoris (No) | 88 | 94 | 92 | 274 |
| Myocardial Infarction (Yes) | 27 | 31 | 33 | 91 |
| Myocardial Infarction (No) | 129 | 126 | 125 | 380 |
| Ischemic Cerebrovascular Disease (Yes) | 79 | 77 | 78 | 234 |
| Ischemic Cerebrovascular Disease (No) | 77 | 80 | 80 | 237 |
| Coronary Arterial Bypass Grafting or PTCA (Yes) | 52 | 51 | 48 | 151 |
| Coronary Arterial Bypass Grafting or PTCA (No) | 104 | 106 | 110 | 320 |
| Other (Yes) | 6 | 10 | 9 | 25 |
| Other (No) | 150 | 147 | 149 | 446 |
The record gives a start of Jul 2011, a primary completion of Mar 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rabeprazole · E-3810